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Abstract
Background: Unimpaired HLA class I antigen presentation is a prerequisite for the recognition of tumor cells by
cytotoxic T lymphocytes and thus essential for the success of anticancer immunotherapeutic concepts. Several
approaches have been taken in the immunotherapy of metastatic renal cell carcinoma (RCC), however of limited
success. HLA loss or down-regulation have often been reported and might interfere with immunotherapeutic
approaches aimed at the recognition of HLA-presented peptides.
Methods: We employed a quantitative method of molecular analysis for the comparison of HLA amounts on
primary tumor, normal kidney and metastases of RCC, using Edman degradation. We analyzed a series of 47 RCC
samples including corresponding renal parenchyma, local lymph node metastases and distant metastases.
Results: Results of quantitative Edman degradation revealed significantly higher HLA yields on primary tumor and
metastases compared to normal kidney tissue. This effect was shown not to result from infiltrating immune cells,
since tumor-infiltrating lymphocytes had no influence on the overall HLA recovery from tumor tissue.
Unexpectedly, we found a higher amount of HLA class I molecules on distant metastases compared to local lymph
node metastases.
Conclusion: Edman degradation allows the direct quantitative comparison of HLA class I protein expression by
tumor or normal tissue and metastases of RCC patients. Our results raise hopes for improving the success and
effectiveness of future immunotherapeutic concepts for metastatic RCC.
Background
Metastatic renal cell carcinoma (RCC) remains a disease
with fatal prognosis that is responsible for almost
100,000 deaths per year [1]. It is the most common
malignant tumor in adult kidney, accounting for
approximately 3% of human malignancies. Metastatic
RCC is still a challenging tumor entity even though var-
ious strategies for chemotherapy have been developed in
recent years [2,3]
The high immunogenicity of RCC has led to several
immunotherapeutic concepts, starting with IFNa/IL-2
treatment [4] and advancing over numerous studies
using cell-based vaccines to vaccination therapy with
HLA-presented peptides derived from tumor-associated
antigens [5-8]. Although some immunotherapeutic
studies for metastatic RCC have found their way into
the clinic [9-11], the clinical results of cancer immu-
notherapy are still below expectation.
Most immunotherapeutic concepts focus on HLA
class I molecules, which are necessary for antigen pre-
sentation to cytotoxic T cells (CTLs). Even today the
critical amount of HLA class I complexes on the cell
surface that leads to T cell activation has still not been
finally clarified - specifications vary between a few thou-
sand and under ten [12,13]. Nevertheless, HLA class I
altered expression on cancer cells still represents one of
the most important mechanisms of tumor escape from
immune response that eventually leads to accumulation
of new variants with low immunogenicity and high
capability for metastatic progression [14,15]. For this
reason, the presentation of HLA class I antigens on
tumor cell surface seems to be one of the main factors
impairing the success and clinical outcome of peptide-
based cancer vaccines aimed at increasing specific
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sion of HLA class I is frequently observed in various
types of malignancies and in some cases it has been
associated with poor clinical prognosis [17-19]. In case
of RCC, the downregulation or loss of HLA-class I has
also been described [20,21], as well as overexpression of
HLA class I on RCC compared to normal kidney tissue
[22]. However, the quantification in these studies was
only determined indirectly with immunohistochemistry
o ro nm R N Al e v e lb yg e n ee x p r e s s i o na n a l y s i s .W h i l e
immunohistochemistry as a semi-quantitative method
sheds a spotlight on only one layer of tissue, mRNA
levels do not always correlate well with protein levels.
Therefore, both methods might yield indirect informa-
tion but only direct analysis of HLA expression on the
protein level is capable of appropriate HLA class I
quantification.
Thus, the aim of this study was to use a well-estab-
lished quantitative molecular method [23] for the direct
comparison of HLA class I molecules presented by
RCC. For this goal we used Edman degradation as a
tool to quantify HLA class I molecules isolated by
immunoprecipitation. This method should easily reveal
quantitative differences between HLA class I presenta-
tion on primary tumor, autologous kidney tissue and
metastases of RCC and by doing so, predict the success
of immunotherapeutic concepts for metastatic RCC.
Methods
Patients and tumor samples
Tissue samples from RCC patients were provided by the
Clinic for Urology, University of Tübingen, Germany.
We acquired tissue from primary RCC tumors, from
corresponding normal kidney, and synchronous or
metachronous metastases which occurred in contiguous
lymph nodes, contralateral kidney or other viscera.
Specimens were frozen in liquid nitrogen immediately
after surgery and stored at -80°C until further use. In
addition, a corresponding vital specimen of tumor tissue
was collected as fresh tissue in RPMI and used by the
T cell monitoring group, Department of Immunology,
University of Tübingen, for collecting tumor infiltrating
lymphocytes (TILs). This study has been approved by
the local ethical review board.
Peptide extraction
Frozen tumor, normal kidney and metastatic tissues
were processed as described previously [24,25]. Briefly,
peptides were isolated according to standard protocols
by immunoprecipitation of HLA molecules from solid
tissues using the HLA-A, -B, and -C specific antibody
W6/32 coupled to CNBr-activated Sepharose (Roche
Applied Science) followed by acid elution and subse-
quent ultrafiltration.
Immunohistochemistry for the detection
of MHC class I molecules
For antigen retrieval formaldehyde-fixed 5 μm paraffin
sections from tumors were heated with 10 mmol/L citrate
buffer (pH 6.0) for 5 minutes at 120°C followed by incuba-
tion with the mouse monoclonal anti-HLA-A/B/C
antibody (clone W6/32, ATCC) for 1 h at room tempera-
ture. Subsequently, the sections were incubated with bioti-
nylated anti-mouse-antibodies (Vector Laboratories, Inc.,
Burlingame, CA) for 30 minutes at room temperature, and
a streptavidin-biotin-immunoperoxidase system (Vectas-
tain Elite StreptABC, Vector Laboratories, Inc., Burlin-
game, CA) followed by DAB (Dako) and counterstained
with hematoxylin. As a negative control, isotype-matched
IgG were used in place of the primary antibody. Slides
were viewed with a Zeiss Axioskop 40 microscope.
Edman degradation
HLA yield was determined by Edman degradation using a
pulsed-liquid protein sequencer Procise 494A (Applied
Biosystems) equipped with a special C18 column for phe-
nylthiohydantoin (PTH) amino acid analysis (Spheri-5
PTH 5 μm, 220 × 2.1 mm; PerkinElmer). Edman degrada-
tion chemistry efficiency is determined primarily by two
chemical reactions. The first is a phenylisothiocyanate
(PITC) coupling reaction to the N-terminus of a protein.
PITC reacts with the free amino (NH2) group, resulting in
an acid labile phenylthiocarbamyl derivative at the N-
terminus of the protein. Subsequently, trifluoroacetic acid
(TFA) is introduced to cleave the modified N-terminal
amino acid from the protein. After further modification to
am o r es t a b l ep h e n y l t h i o h y d a n t o i n( P T H )d e r i v a t i v e ,t h e
derivatized amino acid is chromatographed. The PTH
amino acid is identified by its unique retention time in the
chromatogram. This process is repeated iteratively for
each subsequent terminal amino acid of the protein.
With the known N-terminal sequence of the HLA class I
molecule it is possible to calculate the yield of HLA in
each sample by determining the amount of PTH amino
acids over the sequencing cycles. For this study we
sequenced and analyzed the first seven amino acids of the
HLA class I a-chain (GSHSMRY) which are conserved
among all human class I molecules. Due to background
effects of the abundant amino acids serine and glycine, the
contaminating sequence NIVMTQS from Ig kappa chains,
and varying yields of the somewhat unstable arginine [23],
we focused in particular on the amount of histidine in the
third cycle after subtracting the background value of the
preceding cycle. Recombinant HLA class I monomers
served to verify the reliability of our method. Samples of
tumor, normal tissue and metastases acquired from the
same patient were always sequenced directly in series, thus
avoiding the influence of any day-to-day variation in this
nonetheless quite robust analytical method.
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Results of quantitative Edman degradation were normal-
ized according to the HLA yield from 1 g of tissue. Sta-
tistical analysis for significant differences in HLA yields
was performed using the unpaired Student’st - t e s t
(Graph Pad Prism 5 Software).
Results
The general outline of the study was to establish a
method for direct HLA quantification from lysates of
RCC. We performed immunoprecipitation of HLA class
I molecules using affinity chromatography and deter-
mined the yield of eluted HLA class I molecules by
quantitative Edman degradation. Tissues analyzed within
this study are shown in Table 1. Quantification was
Table 1 Tissue samples and amounts of immunopurified
HLA class I
Tissue
specimen
Tumor (T)
Normal renal
tissue (NK)
Metastasis (M)
Type Mass
(g)
TILs Edman
results
(pmol)
Average
HLA
amount
(pmol/g)
RCC399 NK
T
M( l y m p h
node)
ccRCC 2.4
13.8
1.0
yes 60
1000
40
25.0
72.5
40.0
RCC377 NK
T
M( l y m p h
node)
ccRCC 4.2
12.7
4.5
n.d 500
6000
3500
119.0
472.4
777.8
RCC364 NK
T
M( l y m p h
node)
ccRCC 1.2
5.8
0.4
yes 10
1000
20
8.3
172.4
50.0
Rcc343 NK
T
M (liver)
ccRCC 3.2
2.1
3.2
n.d 20
200
1400
6.3
95.2
437.5
RCC70 NK
T
M( l y m p h
node)
ccRCC 4.4
8.3
2.6
n.d. 300
3200
200
68.2
385.5
76.9
RCC307 NK
T
pRCC 2.7
1.6
n.d. 200
400
74.1
250.0
RCC211 NK
T
pRCC 0.4
20.7
n.d. 10
2100
25.0
101.4
RCC193 NK
T
ccRCC 2.4
4.7
n.d. 500
850
208.3
180.9
RCC131 NK
T
ccRCC 6.5
11.5
n.d. 400
300
61.5
26.1
RCC121 NK
T
ccRCC 6.2
10.4
no 500
460
44.2
80.6
RCC119 NK
T
ccRCC 8.9
7.8
yes 440
560
49.4
71.8
RCC110 NK
T
chRCC 13.0
7.0
yes 1700
3900
130.8
557.1
RCC100 NK
T
ccRCC 12.6
8.0
no 1400
1200
111.1
150.0
RCC99 NK T ccRCC 12.4
7.7
no 1500
1300
121.0
168.8
RCC81 NK
T
chRCC 10.0
18.0
no 1400
1800
100.0
140.0
Table 1 Tissue samples and amounts of immunopurified
HLA class I (Continued)
RCC76 NK
T
ccRCC 6.2
12.8
n.d. 1200
2600
193.5
20.3
RCC71 NK
T
ccRCC 9.0
7.0
n.d. 10
3000
1.1
428.6
RCC58 NK
T
ccRCC 7.6
7.2
no 2000
2400
263.2
333.3
RCC57 NK
T
n.d. 6.8
8.7
yes 1900
2500
279.4
287.4
RCC53 NK
T
n.d. 6.9
6.2
n.d. 1300
1900
188.4
306.5
RCC52 NK
T
ccRCC 7.4
7.0
n.d. 100
2000
13.5
285.7
RCC51 NK
T
chRCC 7.0
7.8
n.d. 2100
2000
300.0
256.4
RCC49 NK
T
n.d. 7.0
8.8
n.d. 1300
2900
185.7
329.5
RCC46 NK
T
n.d. 7.6
9.3
n.d. 400
1500
52.6
161.3
RCC173 NK
M
(contralateral
k.)
ccRCC 5,0
5,1
n.d. 40
240
8.0
47.1
RCC249 T chRCC 2.6 n.d. 80 30.8
RCC231 T pRCC 6.3 n.d. 380 60.3
RCC226 T ccRCC 6.8 n.d. 250 36.8
RCC195 T ccRCC 60.0 n.d. 50 0.8
RCC130 T ccRCC 6.0 no 1100 183.3
RCC125 T ccRCC 15.5,
8.1
n.d. 400 25.8
RCC116 T ccRCC 15.8 yes 2380 150.6
RCC115 T ccRCC 26.0 yes 12900 496.2
RCC113 T ccRCC 10.1 n.d. 200 19.8
RCC108 T pRCC 30.0 yes 1500 50.0
RCC103 T chRCC 10.0 yes 4400 440.0
RCC101 T ccRCC 7.5 yes 800 106.7
RCC98 T ccRCC 21.1 n.d. 2100 99.5
RCC90 T ccRCC 20.0 n.d. 10200 510.0
RCC75 T pRCC 16.0 n.d. 2200 137.5
RCC73 T ccRCC 10.0 n.d. 1300 130.0
RCC68 T ccRCC 20.0 yes 2500 125.0
RCC395 M (lymph
node)
ccRCC 1.4 n.d. 50 35.7
RCC333 M (pancreas) ccRCC 10.9 yes 3000 275.2
RCC328 M
(contralateral k.)
ccRCC 1.5 n.d. 300 200.0
RCC112 M (adrenal
gland)
ccRCC 2.5 n.d. 700 280.0
RCC126 NK ccRCC 8.9 yes 200 22.5
Total and normalized HLA yields of all tissue samples analyzed in this
study. Weight, histological subtype and information about present TILs
are indicated for each examined RCC (tumor, normal tissue and
metastases). HLA typing was carried out by the Institute for Clinical and
Experimental Transfusion Medicine and histologic classification was
performed by the Department of Pathology, University of Tübingen,
Germany. T, tumor; NK, normal kidney; M, metastasis; n.d., not
determined; ccRCC, clear cell renal cell carcinoma; pRCC, papillary renal
call carcinoma; chRCC, chromophilic renal cell carcinoma; no, no TILs
detected; yes, TILs detected.
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From 5 RCC patients we could acquire triplet tissue
samples from tumor, corresponding kidney tissue and
metastases. In addition, 19 autologous pairs of tumor
and normal renal tissue could be analyzed in this study.
From one patient we obtained only normal tissue and a
distant metastasis from contralateral kidney. In addition,
17 single primary tumors, 4 single metastases and 1 sin-
g l en o r m a lt i s s u ew e r ea n a l y z e d .A l le x a m i n e dt i s s u e s
were processed with identical methods and the same
protein sequencer.
HLA yield appeared to be very heterogeneous with
total HLA class I amounts ranging from 10 to 12900
pmol respectively from 0.8 to 777.8 pmol/g for normal-
ized HLA yield (Table 1).
Overall quantitative comparison
Table 1 shows the overall HLA yield determined by
Edman degradation and the normalized HLA yield in
pmol/g. For statistical analyses we used unpaired Stu-
dent’s t-tests to identify significant differences in HLA
yield from different tissues. Overall comparison
between tumor, normal tissue and metastases of all 47
analyzed RCC samples is shown in Figure 1A. The mean
amount of HLA class I was 197.8 ± 24.6 pmol/g recovered
from tumor tissue (n = 40), 102.3 ± 17.9 pmol/g from
normal kidney tissue (n = 26) and 222.0 ± 75.4 pmol/g
from metastases (n = 10). Significant differences in
HLA yield were observed for the comparison of tumor
and normal tissue (p = 0.0062) as well as for metas-
tases and normal tissue (p = 0.0337). The overall
comparison clearly showed an increased yield of HLA
class I from tumor and metastases of RCC compared
to normal kidney tissue. There was also a slight
increase of HLA yield on metastases compared to
tumor tissue but below the level of statistical signifi-
cance (p = 0.69).
Looking at the differences between tumor, normal tis-
sue and metastases in the autologous setting (i.e., sam-
ples acquired from the same individual) to achieve a
direct comparison of the HLA yield (Figure 1B), we
determined the mean amount of HLA class I at 222.2 ±
29.6 pmol/g on tumor tissue (n = 24), 109.6 ±
18.6 pmol/g on normal kidney tissue (n = 24) and 276.4
± 145.7 pmol/g on metastases (n = 5). Again, statistically
significant differences in HLA yield were detected for
the comparison between tumor and normal tissue (p =
0.0023) as well as for the comparison between metas-
tases and normal tissue (p = 0.0329). Comparison
between tumor and metastases showed again a slight
but non-significant increase in HLA yield from metas-
tases, due to low sample numbers. This direct autolo-
gous comparison confirmed the results of the overall
comparison, demonstrating an increased amount of
Figure 1 HLA yields from different tissues were normalized to
1 g of tissue. The mean value of the normalized HLA yield of the
respective tissue type is given plus standard error of the mean
(SEM). Statistical significance of the differences between tissues is
reflected in p values determined by the Student`s t-test and
indicated in the histogram. Amounts of immunopurified HLA class I
compared between: A) Primary tumors (Tumor), normal tissues
(Normal) and metastases of all analyzed tissue samples (overall
comparison). B) Primary tumor, corresponding normal tissue and
metastases obtained from the same patient (autologous
comparison). C) Primary tumor, normal tissue, lymph node
metastases and distant metastases of all analyzed tissue samples.
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to normal kidney tissue.
Differences between local lymph node metastases and
distant metastases of RCC
In order to distinguish between HLA quantities
recovered from lymph node metastases and distant
metastases (derived from pancreas, liver, adrenal gland
and controlateral kidney), we compared tumor and nor-
mal kidney tissue to lymph node metastases and distant
metastases, separately (Figure 1C). The mean amount of
HLA class I detected was 171.3 ± 121.5 pmol/g from
local lymph node metastases (n = 6) and 298.2 ± 49.9
pmol/g on distant metastases (n = 4). Higher HLA yield
from distant metastases compared to normal tissue
showed a statistical significance (p = 0.0005), whereas
the comparison between normal tissue and lymph node
metastases could not reach a level of significance. Thus
HLA presentation on distant metastases of RCCs
appears to be higher than on lymph node metastases.
Impact of tumor infiltrating lymphocytes on the HLA
yield of RCC
In order to rule out the possibility that tumor infiltrat-
ing lymphocytes (TILs) have a strong impact on quanti-
tative HLA analysis by Edman degradation, we
compared primary RCCs from which TILs could be cul-
tured with tumors from which no TILs could be isolated
and cultured (Figure 2). The mean amount of HLA class
I was 230.0 ± 55.9 pmol/g recovered from RCC with
TILs (n = 11) compared to 176.0 ± 34.6 pmol/g from
tumors without TILs (n = 6). This comparison shows
that the HLA amount in tumors containing TILs is
slightly higher than in tumors without TILs. However,
statistical analysis showed no significance; the p value of
0.51 suggests a nearly identical HLA yield on both
tumor groups.
Immunohistochemical analysis of HLA class I expression
We performed immunohistochemistry as a complemen-
tary method to visualize HLA class I expression in dif-
ferent tissues of our patients. Figure 3 shows
exemplarily our findings in RCC377, revealing an abun-
dant HLA class I expression in a lymph node metastasis
as well as a stronger expression in primary tumor cells
in comparison to normal kidney tissue. Within the
lymph node metastasis, epithelial cells and immune cells
contribute to HLA class I expression but tumor cells are
also intensely stained.
Discussion
Edman degradation for quantitative HLA analysis
Although other techniques have in the meantime sur-
passed Edman chemistry in sensitivity, cost, and use for
routine protein characterization, automated Edman
degradation remains the most effective tool for obtain-
ing N-terminal amino acid sequence information, and
represents a reliable quantitative technique in its routine
application [26]. Therefore we chose Edman degradation
with the intention of establishing a method for direct
quantitative analysis of HLA molecules immunopurified
from RCC. To our knowledge this is the first study
comparing HLA yield on tumor, normal tissue and
metastases of RCC using direct quantification. Previous
studies used indirect methods, such as immunofluores-
cence, or analysed the HLA class I expression on
mRNA level [20,27,28].
Considering intrinsic effects of automated Edman
degradation chemistry, such as inefficiencies in the cou-
pling and cleavage reactions as well as different recov-
eries of PTH amino acids, we sequenced and analyzed
the first seven amino acids of the HLA class I a-chain
(GSHSMRY), focusing especially on quantitation of his-
tidine in the third cycle. Raw values were neither cor-
rected for repetitive yields (for the instruments
operating in most laboratories, a 92-94% overall repeti-
tive yield is considered acceptable [26]) nor for initial
yields or PTH amino acid recoveries [23]. The first
monitoring measurements with known yields of recom-
binant HLA class I monomers evinced histidine in
sequence position 3 as most reliable parameter for the
overall HLA amount of the analyzed sample. Other
authors reported of large errors in the calculated
amount of peptides when several different amino acids
Figure 2 Comparison TILs vs. no TILs.A m o u n t so f
immunopurified HLA class I compared between primary tumors
containing TILs and tumor tissue without TILs. Yields were
normalized to 1 g of tissue. The mean value of the normalized HLA
yield of the respective tissue type is given plus standard error of the
mean (SEM). Statistical significance of the differences between
tissues is reflected in p values determined by the Student`s t-test
and indicated in the histogram.
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Page 5 of 9Figure 3 Immunohistochemical staining of RCC377 tissues. Staining with the HLA class I specific antibody W6/32 demonstrates a higher
expression of class I in tumor vs. benign kidney tissue. Expression in metastatic tissue is still higher. Although antigen presenting cells (APC) and
endothelial cells contribute to HLA class I expression, tumor cells localized within this lymph node metastasis are also expressing class I at a high level.
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[26,29].
The aim of this study was not to establish a method
for determining the absolute amount of HLA class I
molecules on the cell surface, but to obtain relative
amounts that are comparable between different types of
tissues. A study of the Edman Sequencing Research
G r o u p( E S R G )s h o w e dt h a tt h er e l a t i v ea m o u n t sc o m -
paring two different samples were highly accurate, the
average error being 6.8% [26].
Thus Edman degradation proved to be an appropriate
method for direct quantitative comparison of HLA class
I molecules immunopurified from tumor, normal tissue
and metastases of RCC patients. We have to emphasize,
however, that rather large samples are required with
respect to the sensitivity of Edman sequencers. Our
study included tissues of far more than 2 g in most
cases; the need for a big sample size prevented the ana-
lysis of larger cohorts.
Results of quantitative HLA analysis
The presentation of HLA class I antigens on tumor cells
represents a major factor in determining the success
and clinical outcome of immunotherapeutic concepts
aimed at increasing specific anti-tumor activity of CTLs.
In order to predict the success of immunotherapeutic
approaches for metastatic RCC, it was decided to com-
pare HLA class I presentation on primary tumor, auto-
logous normal kidney tissue and metastases of renal cell
carcinoma. We performed this comparison on different
levels, including local and distant metastases. To our
knowledge this is the first study determining HLA class
I yield directly on the protein level from RCCs and
metastatic tissue.
The HLA yield was found in most cases to be depen-
dent on the tissue mass (Table 1). Low amounts of HLA
class I recovered from bulky tumors with a mass up to
60 g are presumably due to necrotic decay or stromal
invasion of these tumors in vivo.
The overall comparison of all 47 analyzed tissue sam-
ples (Figure 1) as well as the direct comparison of 24
autologous pairs of tumor and normal tissue (Figure 2)
showed a significantly higher yield of HLA class I from
tumor than normal tissue.
It has to be mentioned that tumors represent het-
erogeneous tissues which contain different subsets of
cells. Although RCC is expected to be more homoge-
nous than, for example, colon carcinoma, the tumors
analyzed in this study might harbor endothelial cells
and - most important - immune cells that could dis-
tort HLA quantification because of their high HLA
expression. To demonstrate that a greater HLA yield
from the tumors was indeed due to a higher HLA
class I amount on tumor cells and not to tumor
infiltrating lymphocytes (TILs), which could be found
in 70% of all renal cell carcinomas (Table 1 and C.
Gouttefangeas, unpublished), we compared primary
RCCs from which TILs could be cultured with tumors
from which no TILs could be isolated (Figure 2).
Although we observed a tendency of TIL-containing
tumors to yield slightly more HLA class I molecules
than the TIL-free samples, the differences were not
statistically significant (p = 0.51) and thus much smal-
ler than the differences between tumor and normal
tissue. From these data there seems to be no major
impact of TILs on the results of quantitative HLA
analysis in RCC tumors. On the other hand, we can-
not rule out completely that endothelial cells or anti-
gen presenting cells [20,21] contribute to the
enhanced recovery of HLA molecules from tumor tis-
sue and in particular from lymph node metastases.
Immunohistochemical staining of tissues, as exempla-
rily shown in RCC377, confirms abundant expression
of HLA class I on the surface of tumor cells but also
endothelial and immune cells. Figure 3 gives an
impression of HLA density on the different subsets of
cell types. As outlined above, however, immunhisto-
chemistry as a semi-quantitative method gives infor-
mation on one layer of tissue only.
Recent reports have described a total or partial loss
of HLA class I for nearly all types of tumors [18,30].
HLA class I downregulation or complete loss was
observed in 10 - 50% of melanomas, breast, lung, col-
orectal, cervix and prostate cancers [19]. In case of
R C C ,d o w n r e g u l a t i o na n dl o s so fH L Ac l a s sIh a sa l s o
been described: The amount of HLA negative tumors
was determined to be up to 37.8% and was correlated
with lower 5-year survival rates [20]. On the other
hand, higher HLA expression in RCC compared to
normal kidney tissue has been reported as well [22,31].
The individual analysis of our study indicates a slight
HLA downregulation on tumor tissue compared to
normal tissue for only 5 of 24 tumors and normal tis-
sue pairs (20.8%) (Table 1), whereas for most of the
tumor tissues considerably higher HLA class I amounts
were quantified. There was no significant difference in
HLA presentation on different subtypes of RCCs inves-
tigated in this study.
Since T-cell based immunotherapy is not expected to
clear bulky tumor masses, many clinical applications
focus on the stage of minimal residual disease. To com-
bat micrometastases remaining after dissection of the
primary tumor, the metastases must express certain
HLA levels and present tumor-associated peptides. In a
recent report we confirmed that tumor-associated HLA
ligands are indeed shared between primary tumors and
metastases [32]. Here, we performed a quantitative com-
parison of HLA class I molecules immunopurified from
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(Figures 1A, B) and detected significantly higher HLA
amounts on metastatic tissue compared to normal
kidney tissue. HLA class I yield from metastatic tissue
was slightly higher than from tumor tissue, but beyond
the level of significance. Contrary to the expectation
that lymph node metastases, due to their higher amount
of immune cells, should contain more HLA class I
molecules, the comparison between lymph node metas-
tases and distant metastases (Figure 1C) revealed a sig-
nificantly higher amount of HLA on distant metastases
than on normal tissue and lymph node metastases.
These findings are in contrast to reports of HLA down-
regulation or loss even stronger in metastases than in
primary tumors [33]. However, HLA loss rates vary
between different tumor entities [34] and there are only
few reports on HLA expression in distant metastases of
RCC. Numerous reports have correlated tumor progres-
sion with downregulation or complete loss of HLA
[16,21,35], for example in metastatic melanoma a high
HLA class I amount (on metastases) correlated with
regression whereas a low HLA amount correlated with
progression under therapy [16]. These facts and our
data hold promise for the success of immunotherapeutic
strategies also against metastatic RCC.
Conclusion
The aim of our study was to establish a direct method
for quantitative analysis of HLA class I molecules
immunopurified from tumor, normal tissue, and metas-
tases of RCC. Edman degradation appears to be a feasi-
ble, effective and reliable method for performing
quantitative direct comparisons of samples of sufficient
size. Our results may contradict other reports, but they
do provide an impulse for improving the effectiveness of
current and future immunotherapeutic concepts for
metastatic RCC. Due to the limited amount of samples
analyzed and the heterogeneity of the individual HLA
yields our results cannot be generalized at present.
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